Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.37 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | BRD2 | P25440 | 2/20 | 0.33 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18067345 | 0.95 | MAP3K5 (0.37) | TOP2AMAP3K5ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL23171525 | 0.87 | MAP3K5 (0.34) | MAP3K5CYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL17992586 | 0.86 | MAP3K5 (0.37) | TOP2AMAP3K5ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL19199895 | 0.85 | MAP3K5 (0.36) | TOP2AMAP3K5ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL22643768 | 0.85 | MAP3K5 (0.36) | TOP2AMAP3K5ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL24252206 | 0.85 | — | — | |
| SCHEMBL16856403 | 0.85 | SLC9A1 (0.34) | TOP2ASMN1; SMN2BRD4BRD2BRD3 | |
| SCHEMBL23837204 | 0.84 | MAP3K5 (0.31) | MAP3K5 | |
| SCHEMBL21901839 | 0.84 | NPY5R (0.38) | TOP2AMAP3K5ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL24496849 | 0.84 | ADRA2A (0.30) | ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044780-A1 | INTERLEUKIN-18 VARIANTS AND USES THEREOF | SUTRO BIOPHARMA, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024015229-A1 | PROTEASE/ENZYME CLEAVABLE LINKER-PAYLOADS AND PROTEIN CONJUGATES | SUTRO BIOPHARMA, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20230330248-A1 | ANTIBODY-DRUG CONJUGATE INCLUDING NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-10-19 | — | — | US | disclosed |
| US-11583590-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-02-21 | — | — | US | disclosed |
| US-11572411-B2 | Anti-CD117 antibodies and conjugates | Magenta Therapeutics, Inc. (US) | 2023-02-07 | — | — | US | disclosed |
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220249683-A1 | T-CELL DEPLETING THERAPIES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2022-08-11 | — | — | US | disclosed |
| US-20220177577-A1 | ANTI-CD117 ANTIBODY DRUG CONJUGATES AND USES THEREOF | Magenta Therapeutics, Inc. | 2022-06-09 | — | — | US | disclosed |
| US-20220175944-A1 | ANTI-CD117 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Magenta Therapeutics, Inc. | 2022-06-09 | — | — | US | disclosed |
| US-20220175946-A1 | CONDITIONING METHODS FOR GENE THERAPY | REGENERON PHARMACEUTICALS, INC. | 2022-06-09 | — | — | US | disclosed |
| US-20200376135-A1 | FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF | Magenta Therapeutics, Inc. (US) | 2020-12-03 | — | — | US | disclosed |
| US-20200368363-A1 | COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD2+ CELLS | MAGENTA THEERAPEUTICS, INC. (US) | 2020-11-26 | — | — | US | disclosed |
| WO-2020221744-A1 | METHOD FOR RADIOIODINATION OR RADIOASTATINATION OF A BIOMOLECULE | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2020-11-05 | — | — | WO | disclosed |
| US-20200276326-A1 | COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD5+ CELLS | MAGENTA THERAPEUTICS INC (US) | 2020-09-03 | — | — | US | disclosed |
| US-20200255523-A1 | FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2020-08-13 | — | — | US | disclosed |
| US-20200207859-A1 | METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN TREATMENT OF T-CELL LYMPHOMA | SUTRO BIOPHARMA, INC. | 2020-07-02 | — | — | US | disclosed |
| WO-2019136442-A1 | CD16A BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
| WO-2019023316-A1 | METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN TREATMENT OF T-CELL LYMPHOMA | SUTRO BIOPHARMA, INC. (US) | 2019-01-31 | — | — | WO | disclosed |
| WO-2017132615-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. (US) | 2017-08-03 | — | — | WO | disclosed |
| WO-2017132617-A1 | ANTI-CD74 ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-CD74 ANTIBODY CONJUGATES AND METHODS OF USING ANTI-CD74 ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. (US) | 2017-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572411-B2 | Anti-CD117 antibodies and conjugates | ITGB7, FUT7, CD2 | TOP2A 4847/4885MAP3K5 2953/4885ALDH1A1 197/4885 |
| US-20200255523-A1 | FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF | FCGR1A, FCGR2A, FCGR3B | TOP2A 4481/4885MAP3K5 4087/4885ALDH1A1 278/4885 |
| US-20220175944-A1 | ANTI-CD117 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | ITGB7, KIT, CD2 | TOP2A 4662/4885MAP3K5 2404/4885ALDH1A1 93/4885 |
| US-20220177577-A1 | ANTI-CD117 ANTIBODY DRUG CONJUGATES AND USES THEREOF | SIGLEC7, FUT7, ITGB7 | TOP2A 4634/4885MAP3K5 2487/4885ALDH1A1 173/4885 |
| US-20200376135-A1 | FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF | FCGR1A, FCGR2A, FCGR3B | TOP2A 4481/4885MAP3K5 4087/4885ALDH1A1 278/4885 |
| US-20230330248-A1 | ANTIBODY-DRUG CONJUGATE INCLUDING NOVEL CYCLIC DINUCLEOTIDE DERIVATIVE | STING1, CGAS, TLR9 | TOP2A 468/4885MAP3K5 1634/4885ALDH1A1 3436/4885 |
| US-20200207859-A1 | METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN TREATMENT OF T-CELL LYMPHOMA | CD74, CD99, CD2 | TOP2A 152/4885MAP3K5 4813/4885ALDH1A1 1734/4885 |
| US-20220175946-A1 | CONDITIONING METHODS FOR GENE THERAPY | CD74, CD2, CD44 | TOP2A 2367/4885MAP3K5 4041/4885ALDH1A1 118/4885 |
| US-20200276326-A1 | COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD5+ CELLS | CD59, CD58, CD47 | TOP2A 3700/4885MAP3K5 3690/4885ALDH1A1 651/4885 |
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | TOP2A 3396/4885MAP3K5 1962/4885ALDH1A1 1203/4885 |
| US-20220249683-A1 | T-CELL DEPLETING THERAPIES | CD2, CD4, CD22 | TOP2A 3521/4885MAP3K5 3751/4885ALDH1A1 208/4885 |
| US-20200368363-A1 | COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD2+ CELLS | CD2, CD22, CD2BP2 | TOP2A 3109/4885MAP3K5 3989/4885ALDH1A1 317/4885 |
| US-11583590-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor | EPCAM, PDCD6, CNTN1 | TOP2A 933/4885MAP3K5 3634/4885ALDH1A1 3237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.